BRIEF-Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024

Reuters2023-10-18

Oct 18 (Reuters) - Baudax Bio Inc :

* BAUDAX BIO ANNOUNCES CORPORATE UPDATE

* BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024

* BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS RELATED TO TERAIMMUNE ACQUISITION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment